PremiumThe FlyBristol deal takes out ‘key’ potential buyer of Summit Therapeutics, says Truist Biotech Alert: Searches spiking for these stocks today SMMT, MTDR, FTAI: 3 High-Potential Russell 2000 Stocks with Strong Buy Ratings PremiumThe FlySummit Therapeutics announces topline results from Phase 3 HARMONi trial Summit Therapeutics: Buy Rating Backed by Promising Ivonescimab Trial and Favorable PFS Outcomes Summit Therapeutics Positioned for Growth: Buy Rating Supported by Strategic Value and Acquisition Potential PremiumThe FlyBioNTech price target lowered to $132 from $140 at Morgan Stanley Summit Therapeutics’ Earnings Call: Ivonescimab’s Promising Progress Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz 
